Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.
about
Current efforts and future prospects in the development of live mycobacteria as vaccinesDietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guérin ΔureC::hly Δpdx1 in mice.Modeling tuberculosis in nonhuman primates.Mycobacterium tuberculosis metabolismStable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG VectorsNovel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsA recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaquesGene Transfer in Mycobacterium tuberculosis: Shuttle Phasmids to Enlightenment.Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.The non-human primate model of tuberculosis.BCG immunotherapy for bladder cancer--the effects of substrain differences.Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.Non-pathological infection of macaques by an attenuated mycobacterial vaccine is not reactivated in the setting of HIV coinfection.A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model.
P2860
Q28087077-D8E2543E-B8CC-437D-A06C-C69FDD6CBC12Q33724934-5FBFE8E1-CD89-497E-A606-33DB87EDE345Q34930509-EB4783A0-B84E-455D-9F64-4D926EE77884Q35245286-DCB0FCDA-6E41-4323-8565-8141F262378FQ35773904-1258DF1B-DA46-4441-BA94-395AE18EB47CQ35826779-15918509-1CB7-424B-8D80-918729034D2DQ36154750-DE64F2CB-46B7-46C2-8AE4-F5E33C6F8EBBQ36498586-94E35A76-E3C1-4447-9F4E-32AB1A229E43Q36759963-03392BAE-DA8F-465A-9D49-D2DEE0183A6DQ37563616-9CFA64BD-E823-4784-97B6-A5D2640D29F4Q37652734-D8BBA9DF-6EB4-45CB-BD1A-6A20935CCD42Q38138412-B1F7148D-5108-47BA-BF70-C48B79838C9AQ38385719-FE6E1923-9137-4627-9D13-4646C98F1E7DQ41932554-17A1EEA0-D141-4B34-9E15-4BDCE7AA9AF7Q47136561-51E7BF1F-9F37-4411-86BA-1F822A417D2B
P2860
Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@ast
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@en
type
label
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@ast
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@en
prefLabel
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@ast
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@en
P2093
P2860
P1433
P1476
Extended safety and efficacy s ...... ulosis as a vaccine candidate.
@en
P2093
Angela Carville
Barry R Bloom
D Mitchell Magee
Elizabeth W Howerth
Keith G Mansfield
Mary K Hondalus
Teresa Quitugua
P2860
P304
P356
10.1016/J.VACCINE.2011.04.066
P407
P577
2011-05-05T00:00:00Z